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Abstract
The increasing ratio of ageing population poses new challenges to healthcare systems. The elderly frequently suffer 
from severe infections. Vaccination could protect them against several infectious diseases, but it can be effective only if 
cells that are capable of responding are still present in the repertoire. Recent vaccination strategies in the elderly might 
achieve low effectiveness due to age-related immune impairment. Immunosenescence affects both the innate and 
adaptive immunity.
Beside individual variations of genetic predisposition, epigenetic changes over the full course of human life exert 
immunomodulating effects. Disturbances in macrophage-derived cytokine release and reduction of the natural killer 
cell mediated cytotoxicity lead to increased frequency of infections. Ageing dampens the ability of B cells to produce 
antibodies against novel antigens. Exhausted memory B lymphocyte subsets replace naïve cells. Decline of cell-
mediated immunity is the consequence of multiple changes, including thymic atrophy, reduced output of new T 
lymphocytes, accumulation of anergic memory cells, and deficiencies in cytokines production. Persistent viral and 
parasitic infections contribute to the loss of immunosurveillance and premature exhaustion of T cells. Reduced 
telomerase activity and Toll-like receptor expression can be improved by chemotherapy. Reversion of thymic atrophy 
could be achieved by thymus transplantation, depletion of accumulated dysfunctional naive T cells and herpesvirus-
specific exhausted memory cells. Administration of interleukin (IL)-2, IL-7, IL-10, keratinocyte growth factor, thymic 
stromal lymphopoietin, as well as leptin and growth hormone boost thymopoiesis. In animals, several strategies have 
been explored to produce superior vaccines. Among them, virosomal vaccines containing polypeptide antigens or 
DNA plasmids as well as new adjuvanted vaccine formulations elicit higher dendritic cell activity and more effective 
serologic than conventional vaccines responses in the elderly. Hopefully, at least some of these approaches can be 
translated to human medicine in a not too far future.
1. Background
The global population, especially in the developed coun-
tries, is ageing. The percentage of the population that is
elderly (≥60 years of age) now represents a larger propor-
tion than ever before: it has increased from 8% in year
1950 to 10% in 2000, and this trend is expected to con-
tinue, to reach 21% of the population by 2050 [1]. People
are living much longer than they used to and the longer
they live, the longer their bodies are exposed to environ-
mental factors which increase the risk of age-associated
diseases [2]. The elderly suffer from more frequent and
more severe community-acquired and nosocomial infec-
tions than younger people, and they tend to experience
poor outcomes from infections in comparison to the
younger population [3,4]. The clinical presentation is
often atypical creating diagnostic difficulties. Latently
carried intracellular pathogens such as viruses (e.g. mem-
bers of Herpesviridae), bacteria (e.g. Mycobacteria) or
fungi (e.g. Candida) reactivate and opportunistic infec-
tions manifest themselves at increased rates [5]. In West-
ern countries, the mortality rate increases in people over
65 years, if compared to individuals between 25- and 44-
year old, e.g. 89-fold for pneumonia and influenza or 43-
fold for cancer [2]. Collectively, these diseases severely
influence the quality of life of the elderly and their fami-
lies and greatly challenge public healthcare systems.
Therefore, prevention of these infections becomes criti-
cally important. The most important reason for the
increased rate of infections (and cancers) in the elderly is
believed to be the diminished or exhausted function of
the immune system which occurs with ageing (immu-
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nosenescence, immune exhaustion). Vaccination could
protect the elderly against several infections and possibly
cancer [1,4,6], but at least a partial restoration of age-
related immune deficits seems to be a pre-requisite for
the success of any vaccination regimen in older people.
2. Natural factors affecting the ageing of the 
immune system and their elimination
Immunosenescence due to deregulated immunity [7] is a
very complex process and remains to be fully understood
[1]. Normal ageing is determined genetically, but several
external factors might affect immunosenescence posi-
tively or negatively. Indeed, according to modern views
the actual state of the immune system in the elderly is the
result of a continuous remodelling process [8]. Oxidative
stress is believed to be a major factor of accelerated age-
ing, possibly due to an increased pace of telomere short-
ening resulting from DNA damage. Telomeres are
DNA+protein complexes at the end of chromosomes and
are supposed to be the molecular clock of ageing, includ-
ing that of the immune system, especially lymphocytes
[9]. The shortening of telomeres is due to diminished
activity of telomerase that fails to add telomere repeat
sequences to the end of chromosomes [2,9]. Senescence
can be prevented or reversed using telomerase-based
approaches [1]. Gene therapy using catalytic human
telomerase could improve the function of immune cells
[10]. Furthermore, chemotherapeutic agents acting on
the catalytic component of human telomerase, such as
TAT2, a small molecule telomerase activator, could stabi-
lise telomerase length and retard loss of immune control
over microbial infections [2]. Biotech companies ought to
take the challenge of finding additional ways to prevent
telomerase shortening.
Gender differences in life expectancy are partially
based on altered immune functions: e.g. androgen hor-
mones are known to contribute to thymic involution.
Sociodemographic factors also exert a major impact on
susceptibility to age-related diseases; these include resi-
dency, institutionalisation, income, level of education, life
style and disability in daily living. Unhealthy habits,
comorbidities and medications also contribute to declin-
ing immune activity. Among these, it is worth mentioning
smoking, alcoholism, chronic obstructive pulmonary dis-
eases, hypertension, stroke, heart failure, diabetes melli-
tus, rheumatic and autoimmune diseases and treatments
with chronic oral glucocorticosteroids, as well as severe
cognitive impairment, Alzheimer disease [2], chronic
stress, chronic antigenic stress with consequent inflam-
mation, and many others [11]. Malnutrition is associated
with a decrease in immunity and an increase in suscepti-
bility to many infectious diseases. Both of these effects
are exacerbated by ageing. Underweight may contribute
to an increased mortality by some infectious diseases due
to an inability to meet the energy demands associated
with the immune response to selected microbial infec-
tions [12]. Interventions on nutrition could have a larger
impact on immune functions than commonly appreci-
ated. Vitamin A contributes to the maintenance of epithe-
lium integrity in the respiratory and gastrointestinal
tracts. Vitamin E regulates lipid rafts and membrane flu-
idity on the surface of immune cells and reconstitutes
immunological synapse formation, as clearly demon-
strated in naive CD4+ T cells of old mice [5,13]. Vitamin E
supplementation reduces the risk of influenza virus infec-
tion in aged people. Vitamin D enhances activation of
Toll-like receptors (TLRs) and increases cathelicide pro-
duction, the latter of which contributes to the destruction
of intracellular Mycobacterium tuberculosis. Among the
trace elements, zinc is especially important because it
maintains the activity of more than 300 enzymes includ-
ing those in polymorphonuclear phagocytes, natural
killer (NK) cells and the complement cascade [5]. Anti-
inflammatory nutritional intervention could be especially
useful [14]. Modulating lipid intake may also be benefi-
cial; e.g. conjugated linoleic acid can result in decreased
pro-inflammatory cytokine secretion and has been
reported to increase the success rate of hepatitis B vacci-
nation in the elderly [15]. The lipid environment strongly
influences T cell functions through alterations in the
membrane fluidity of these cells [16]. Human high den-
sity lipoprotein (HDL) has anti-inflammatory and anti-
oxidative effects; HDL extracts accumulated cholesterol
in lipid rafts, resulting in increased T cell receptor (TCR)
signal transduction and T cell activation [17]. Caloric
restriction, that was shown to improve immune respon-
siveness in rodents [18], has also been found to delay T
lymphocyte immunosenescence in non-human primates,
preserving the number and function of naive T cells, and
to reduce pro-inflammatory states [19]. Moderate exer-
cise also serves as an anti-ageing common-sense medical
advice. Aerobic exercise, weight loss and cessation of
smoking can raise HDL levels [17], while participation in
regular physical activity has been seen to lower the
increase in proinflammatory cytokine IL-6 and C-reac-
tive protein (CRP) that occurs with age [8]. Elderly people
with known risk factors could be advised to reduce expo-
sure to these factors (e.g. to stop smoking or unnecessary
use of glucocorticoids) [11]. Not only all types of malig-
nancy but also many therapeutic procedures used in their
treatment impair the immune functions in a vicious cir-
cle. Chemo- and radiotherapy, as well the immunosup-
pressive drugs used in connection with organ
transplantation are well known examples [11].
Beside individual genetic predisposition to immunose-
nescence, epigenetic changes accumulating over the full
course of human life in the cells due to environmental
effects basically determine the quality of life in theOngrádi and Kövesdi Immunity & Ageing 2010, 7:7
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elderly. Major epigenetic mechanisms include DNA
methylation, histone modifications such as methylation,
acetylation, phosphorylation, structural modifications of
the chromatin, and the preferential production of
selected microRNAs. DNA hypomethylation in CpG rich,
promoter-associated regions and acetylated histones
allow active transcription, while DNA hypermethylation
and histone hypoacetylation promote gene silencing. The
changes may be one or two orders of magnitude greater
than the rate of somatic mutations. They are reproduced
during DNA replication and are therefore stably trans-
mitted to the daughter cells including immune cells. Diet
in particular can influence methylation by modulating
the availability of methyl donors including folate, choline,
and methionine. Low levels of methionine early in life
results in longer life and relative preservation of immune
functions. This supports an important role of methyl diet
and life-extending caloric restriction. Protein restricted
diet of rats induced hypomethylation. Lymphocyte func-
tion-associated antigen-1 (LFA-1), which is involved in T
cell activation, is overexpressed in the T cells of elder
people and patients with systemic lupus erythematosus
(SLE). Inhibition of DNA methylation increases LFA-1
overexpression. Acetylation of histone H4 and phospho-
acetylation of H3 following proinflammatory signals
result in the increased activity of NF-κB and consequent
increase in the production of IL-6, the levels of which
augment with age. Treatment of phytohaemagglutinin
(PHA)-stimulated peripheral blood lymphocytes with a
histone deacetylase (HDAC) inhibitor resulted in
hypoacetylation of histone H4 with increasing age. In
similarly treated mice, in vivo production and suppressive
function of Foxp3+CD4+CD25+ regulatory T cells (Treg)
were increased. Epigenetic mechanisms linked to ageing
are believed to contribute to diminished anti-tumour
immunosurveillance, either [refs. in [8]].
Both innate and adaptive immune responses are
affected by age-related deficits. Deterioration of the
innate immunity appears to be the prevalent mechanism
associated with age-related infections, while humoral
immunity retains most of its original activity throughout
the life span [2,20]. It is worth remembering that innate
immune responses are a first step toward the develop-
ment of adaptive immune responses, and that age-related
deficits in innate immune functions might therefore alter
both cell-mediated and humoral adaptive immune reac-
tions [21].
3. Impact of ageing on innate immunity and its 
restoration
Innate immunity is a key element of the immune
response including several cellular components such as
macrophages, NK cells, and neutrophils, which provide
rapid first-line defence against pathogens. The function
of these cells declines with age. Although their produc-
tion increases with age, in the elderly macrophages have a
reduced ability to secrete tumour necrosis factor (TNF), a
key inflammatory cytokine [22]. Macrophage-derived
TNF and interleukin (IL)-1 are essential for the secretion
of other cytokines critical for bone marrow stromal integ-
rity, such as IL-6, IL-11, monocyte colony stimulating fac-
tor (M-CSF), granulocyte-monocyte (GM)-CSF and
receptor activators of NF-κB ligand [23]. Ageing also
dampens the secretion of IL-7 by bone marrow stromal
cells [24]. IL-7 is an essential survival cytokine for devel-
oping lymphocytes [25]. Furthermore, the innate immune
system detects pathogens using pattern-recognition
receptors such as the TLRs, which recognise specific
molecular patterns present on the surface of pathogens.
TLRs are expressed on a variety of cells including mac-
rophages. Interaction between TLRs and a pathogen
stimulates the secretion of a wide range of antibacterial
peptides that destroy the pathogen and trigger an inflam-
matory response through cytokine and chemokine secre-
tion. Studies in humans and mice have shown that TLR
expression and function decline with age [1] resulting in
the decreased production of pro-inflammatory cytokines
and chemokines as well as in the deregulation of the
adaptive immune system [1]. Modulation of the innate
immune system either with TLR ligands or the products
of TLR activation may enhance disease resistance,
immune response and vaccine effectiveness in older per-
sons [1]. TLR ligands may strongly enhance IL-2 produc-
tion, too [26]. Similarly to what observed with other cell
types, both the chemotactic and phagocytic activities of
neutrophils show reduced efficacy with ageing [1,27].
Beside this reduced ability to eliminate microbes, ageing
macrophages and neutrophils cannot destroy cancer cells
either [2].
NK cells account for about 10-20% of peripheral blood
lymphocytes. Most mature NK cells (approximately 90%)
express high levels of FCγRIII (CD16) and are CD56dim.
Proliferation of NK cells primarily occurs in the bone
marrow from the same common progenitor cells as T
lymphocytes. Immature NK cells undergo a serial matu-
ration process. Finally, full functional capabilities are
acquired before they are released into the circulation.
Survival of mature NK cells is cytokine-dependent: IL-15
appears to prolong survival via the anti-apoptotic factor
Bcl-2 [28]. NK cells also play a role in the interactions
between innate and adaptive immune responses. NK cell
function and dynamics may be affected by ageing. Age-
related reductions in NK-cell-mediated cytotoxic activity
appear to be clinically relevant as they are associated with
an increased risk of infection and death in elderly sub-
jects. In mice, basal NK cell function appears to remain
intact in advanced age, whereas the inducible NK
response decreases, although this effect is not observedOngrádi and Kövesdi Immunity & Ageing 2010, 7:7
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consistently in humans [29]. This functional impairment
is not related to a reduction in NK cell numbers, as this
tends to be well maintained or to increase with ageing
possibly due to superior preservation of telomere length.
The production rate of NK cells is approximately halved
in elderly people due to impaired IL-2 responsiveness.
Furthermore, long-lived cells dominate within their NK
cell population. Certain viral infections also affect NK
cells differently from what observed in the young. For
example, chronic infection with human T-lymphotropic
virus-1 does not perturb NK cell dynamics in the young
but decreases NK cell production in old people [8].
It is important to recall that NK cell deficiencies have
been shown to predispose to Epstein-Barr virus (EBV),
cytomegalovirus (CMV), varicella-zoster virus and her-
pes simplex virus (HSV) infections [28]. Since normal NK
cell activity contributes to human health and longevity
[29], the decline of these cells may offer an explanation
for the increased incidence of bacterial and viral pneumo-
nia, as well as gastrointestinal and skin infections in old
age [1]. Clinicians also recognise that older individuals
often have difficulties in dealing with pathogens which
they had previously easily overcome, including the annual
return of influenza. This infection is associated with con-
siderable morbidity and mortality in the elderly. Those
over 65 years of age account for more than 90% of the
deaths from influenza and have an increased likelihood to
develop complications such as pneumonia [4,30]. Epide-
miological evidence reveals that older individuals are
often the first to be affected by new or emerging patho-
gens such as West Nile virus (WNV). During an epidemic
of WNV in the United States in 2002, the majority of
cases occurred in patients over 50 years of age. This epi-
demic caused 4156 cases, of which 284 were fatal; the
median age of the deceased was 78 years of age [31].
Effective vaccination may not only protect against the
specific pathogen targeted, but also may result in
enhanced activity of the NK cell system, which in turn
may be associated with superior specific vaccine
responses [32]. The ineffective protection against
microbes in the muco-cutaneous barriers, including the
breakdown of local immunity in the gingival and oral cav-
ity as well as in the urinary and gastrointestinal systems
that are so frequent in the elderly, may all be expressions
of diminished innate immunity [5].
4. Changes of humoral immunity in the elderly
Haematopoietic stem cells (HSCs) give rise to all cellular
components of the immune system (lymphoid and myel-
oid). Although the haematopoietic compartment of bone
marrow decreases with age, age does not appreciably
affect the number and proliferative capacity of HSCs.
However, through the normal maturation process, there
is a block between the pro- and pre-B cell stage.
Decreased responsiveness of developing B cells to IL-7
[7], decreased V-DJ recombination of immunoglobulin
(Ig) genes, decreased expression of surrogate light chain
λ5, and decreased activity of the transcription factors E12
and E47 with consequent alterations in Ig heavy chain
expression, all play a key role in the pro-to-pre-B cell
block. In a vicious circle, aged bone marrow stromal cells
have a reduced ability to support B cell expansion due to
decreased IL-7 production. Peripheral B cell number also
changes with age, but reports are conflicting [33,34].
Studies in mice demonstrated that, in spite of reduced
input of naïve B cells to the circulation, the overall
peripheral B cell number did not decline with age [33,35]
due to the presence of long lived memory cell subsets [36-
39]. On the contrary, there is a disagreement concerning
the number of mature B lymphocytes in humans. Some
showed a significant increase [39,40], others found a dra-
matic declination of CD27+ cells [39,41,42]. Recent care-
ful dissection of B cell subsets have revealed that a slight
increase in CD27+ memory cells plus a significant
increase of anergic, exhausted memory cells with CD27
down-regulation (CD27-) filled the B immunologic space
in the elderly [34,43]. Novel studies on the offsprings of
centenarians have revealed that these people in their 70s
and 80s had a survival advantage when compared with
age-matched children of parents with average life span. In
both groups a decreased B cell count was observed, how-
ever, in the centenarian offsprings, naïve B cells produc-
ing IgD (IgD+CD27-) were more abundant whereas
exhausted memory cells (IgD-CD27-) did not show the
increase previously had been demonstrated in healthy
elderly individuals. Authors concluded that the reservoir
of naïve B cells might be one of the factors that make cen-
tenarian offsprings able to keep fighting off new infec-
tions, hence prolonging their life. So, the loss of naïve B
cells represents a hallmark of immunosenescence [43,44].
The quality of the humoral immune response declines
with age. This change is characterised by lower antibody
responses and decreased production of high-affinity anti-
bodies. B cell proliferation declines in aged mice due to
declining B cell activation and defective surface Ig/B cell
receptor affinity and signalling [45]. Aged CD4+ T helper
cells provide an inadequate assistance in germinal centres
and promote low-affinity antibody production [46] due to
decreased IL-2 and IL-4 release [47]. B cell progenitors
undergo maturation and differentiation in secondary
lymphoid tissues, such as the spleen and lymph nodes.
These organs provide a highly organised structure for T
and B cells to interact with one another and with antigen
presenting cells (APCs), namely dendritic cells (DCs) and
macrophages. Age-associated reduction of the cortex
lymphocyte cellularity and germinal centres and a parallel
increase in adipose tissue indicate a decreased ability to
provide the proper environment for immune reactions toOngrádi and Kövesdi Immunity & Ageing 2010, 7:7
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take place. Ineffective cooperation of the lymphocytes
within the spleen and lymph nodes and shrinkage of the
germinal centres are known to occur with age. Increased
frequency of B cells and memory CD4+  T cells and
increased expression of the senescence marker p16INK4a
on B cells and CD8+ T cells, accompanied by a decrease
in the number of γ/δ T cells, naive CD4+ T cells, CD8+ T
cells, and IgM producing B cells were observed in the
lymph nodes of aged people [48]. The homing of imma-
ture B cells to the secondary lymphoid organs has been
shown to decrease across the lifespan [49], thus reducing
the chance that an antigen will be recognised by its anti-
gen-specific B cells and possibly reducing the pool of
naive B cells. This results in the loss of naive B cells and
an increase in memory cells with age [49,50], dampening
the ability to respond to novel antigens as the subject
ages. Memory cells produced early in life remain normal
[51]. In fact, B cell memory may be maintained for a very
long time: e.g. individuals who survived the Spanish flu
still had specific antibodies 90 years later and possessed
circulating B cells that secreted binding antibodies for the
haemagglutinin of the H1N1 influenza virus that caused
the pandemic [52].
Ageing is associated with a shift from the Th1 to the
Th2 cytokine profile in response to immune stimulation.
The overproduction of Th2 cytokines could augment B
cell mediated autoimmune disorders by enhancing the
production of autoreactive antibodies. The percentage of
naïve follicular B cell declines, whereas subsets of anti-
gen-experienced mature B cells with longer life span
increase including poly/self-reactive subtypes. These cells
may be reactivated due to age-associated reduction in
immune tolerance or loss of tissue integrity leading to the
exposure of neo-self antigens that result in aberrant auto-
immune response [8].
5. Age-related decline of cell-mediated immunity
The bone marrow supports the generation of T cell pro-
genitors. Studies in aged mice have shown a reduction in
the number and proliferation of early T lineage progeni-
tors defined by surface expression of Lin-, CD44+, c-Kithi,
and IL-7Rαneg/lo [53]. Thymocyte progenitor cells enter
the thymus and through several steps differentiate into
single CD4+ or CD8+ naive T cells, which are exported to
the periphery [21]. The T cell education process is regu-
lated by cytokines and hormones, as well as by epithelial
cells and DCs, macrophages and fibroblasts that make up
the thymic stroma [54]. Production and maintenance of
the diverse peripheral T cell repertoire are critical to the
normal function of the immune system [25]. In the
elderly, there is a decrease in the diversity and functional
integrity of both the CD4+  and CD8+  T-cell subsets,
which contributes to a decreased ability to respond ade-
quately to reinfection [55]. Age-associated changes in
cell-mediated immunity strongly depend on thymic func-
tions [1]. As an individual ages, the thymus undergoes a
progressive involution, and the output of new cells falls
significantly. Thymic functions gradually start decreasing
from year one of life [56], but the process becomes signif-
icant from around year 40 onwards [57]. Increased levels
of sex hormones might contribute to this process [58].
Both the thymic epithelial space, in which thymopoiesis
occurs, and the non-epithelial, non-thymopoietic
perivascular space show morphological and functional
alterations. The expansion of the perivascular space (adi-
pocytes, peripheral lymphocytes, stroma) with age results
in a shift in the ratio of true thymic epithelial space to
perivascular space. On the contrary, the thymic epithelial
space shrinks to less than 10% of the total thymus tissue
by 70 years of age. When extrapolated, data suggest that
the thymus would cease to produce new T cells at
approximately 105 years of age [59]. This fact might
strongly contribute to limit maximum human lifespan. In
addition to age-related thymic atrophy, chemotherapy,
irradiation prior to transplants, septic shock and acute
stress in general also lead to thymic atrophy. Deficiencies
of leptin or leptin receptor in mice elicit chronic thymic
atrophy [60] suggesting a key regulatory role for leptin in
thymopoiesis. Leptin also protects against bacterial endo-
toxin-induced thymic atrophy [61]. Thymic atrophy
m i g h t  a ls o  r es u l t  fr o m  a g e i n g  o f  t h e  T  c e l l  p r o g e n i t o r
population. Similar to what occurs in bone marrow and
peripheral sites, cytokines within the thymus are crucial
for thymopoiesis. Thymic epithelial cells produce a num-
ber of colony-stimulating factors and haemopoietic
cytokines such as IL-1, IL-3, IL-6, IL-7, transforming
growth factor (TGF)-β, oncostatin M (OSM) and leukae-
mia inhibitory factor (LIF). Thymic atrophy and
decreased thymopoiesis are active processes mediated by
the upregulation of thymosuppressive cytokines, espe-
cially IL-6, LIF and OSM in aged human and mouse thy-
mus tissue [25,54], while IL-7 production by stromal cells
significantly decreases [62]. IL-7 is necessary for thy-
mopoiesis, promoting cell survival by maintaining the
anti-apoptotic protein Bcl-2 and inducing V-DJ recombi-
nation [63]. The above changes result in the decreased
thymic output of naive T cells (CD45RA+, CD28+ and
CD45RA+,CD28+,CD26L) and in the decreases concen-
tration of these cells in peripheral blood and lymph nodes
observed during ageing [25,48]; consequently, there is a
shift in the ratio of naive to memory T cells in the periph-
ery to maintain peripheral T cell homeostasis. Naive T
cells from aged mice exhibit reduced activation, differen-
tiation and cytokine production following antigen pre-
sentation [51]. Relative to memory cells generated from
young naive cells, Th1 memory cells derived from aged
naive cells produced much less IL-2; furthermore, Th2Ongrádi and Kövesdi Immunity & Ageing 2010, 7:7
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memory cells derived from aged naive cells produced
much less IL-4 and IL-5 [25]. Aged CD4+ T cells have
decreased CD40L [64], a critical co-stimulatory ligand for
T-B cell interactions, due to IL-2 deficiency. Furthermore,
impaired T-B cell interactions significantly contribute to
the impairment of humoral responses in the aged [51].
Memory T cell activation has also been found to be atten-
uated, showing reduced signalling capacity and prolifera-
tion. Memory T cell function in aged mice seems to be
dependent upon when the response was initiated, since
memory cells produced early in life are normal [51].
Other data show that proliferative responsiveness, inter-
feron (IFN)-γ secretion and antiviral (anti-influenza and
anti E55+ retroviral) capacity of cytotoxic CD8+ T-cells
are severely compromised as a result of ageing [65].
In the course of T-cell dependent immune responses,
naive T cells must be activated by appropriate contact
with APCs, especially DCs, and undergo extensive clonal
expansion. Although antigen presentation by DCs gener-
ally seems to be only subtly different in the elderly in
many respects, there are quantitative differences, with
less numerous peripheral blood and follicular DCs [27].
Chemotaxis and phagocytosis may be impaired in DCs
from the elderly. DCs from young and elderly people are
reported to stimulate naive CD8+ T cells equally well, but
those from the elderly may fail to stimulate naive CD4+ T-
cells properly, perhaps due to altered signal transduction
pathways [59]. These processes depend on either the
number or the structure of cell surface receptors [7]. The
number of TCR molecules per T cell does not change
with age, however there are clear alterations in the num-
ber and balance of receptors that mediate positive or neg-
ative co-stimulatory signals [7]. There is no evidence for
alterations in the actual structure of TCRs or co-stimula-
tory receptors with age, but it is likely that the assembly
of these molecules into functional units is compromised
leading to altered signal transduction. One factor that
influences TCR assembly is cell membrane fluidity. The
increased levels of cholesterol which occur commonly in
the elderly might well contribute to age-associated defi-
cits in T cell signalling. Elderly people possess reduced
levels of tyrosine kinase Lck which is essential for T cell
stimulation [66]. During maturation, thymocytes rear-
range their TCR genes [25]. To mount an adequate
immune response, a broad TCR repertoire must be main-
tained by ensuring the continuing presence of a diverse
population of T cell clones, but this repertoire decreases
with age. There is a corresponding reduction in the diver-
sity of the naive TCR repertoire, which explains the
decreased ability of the elderly to resist infections to
which they were not previously exposed, or to respond to
new antigens [7]. At least for CD4+ T-cells, this may occur
quite suddenly with TCR diversity well maintained up to
age 60-65 years, despite marked decreases in thymic out-
put. However, repertoire diversity in the 75-80 year old is
severely reduced [55], probably contributing to the poor
responses to infection and vaccination in this age group.
In addition, in the elderly about 10% of T cells express the
senescence marker CD57, which is instead rather infre-
quent in the young [1]. On the contrary, approximately
40% of naive T cells of old people do not express the T cell
homing receptors CD62L and CCR7, probably implying
that these cells cannot migrate properly to peripheral
lymphoid tissues to encounter APCs [1].
I n  r e c e n t  y e a r s ,  a n  i m p o r t a n t  r o l e  o f  C D 4 +,CD25+,
Fox3+  regulatory T cells (Treg) in the maintenance of
immune homeostasis has been described [21,67]. Charac-
terization of these cells from young and elderly donors
revealed that those in poor health conditions of either age
group had significantly more Treg cells than their healthy
counterparts. In healthy adults (aged 20-60 years) an
average 0.6-8.7% of CD4+ T cells are regulatory ones.
Aged individuals (> 65 years) have an increase in periph-
eral blood Treg cells, but the lack of IL-7 receptor (CD127)
expression on the surface of these cells results in their
functional damage [68]. Treg lymphocytes downregulate
the immune response after elimination of an antigen [6],
control the host immune response to prevent damages to
host tissues [69], and protect the host from self-reactive
lymphocytes by deleting autoreactive immunocompetent
cells. I t has been suggested that a decrease in T reg cell
numbers or function could result in autoimmune diseases
or rejection of a transplant, while an excess of Treg lym-
phocytes might contribute to poor responses to infec-
tious diseases, vaccines and cancer [69]. A major obstacle
to therapeutic vaccination for chronic infections, such as
human immunodeficiency virus (HIV), hepatitis C virus
(HCV) and M. tuberculosis is to overcome the immuno-
suppressive effects of pathogen-specific Treg cells [21].
Removal of these cells using an anti-CD25 depleting anti-
body prior to immunization with a DNA or peptide vac-
cine against HSV type 1 enhanced CD8+ T cell response
to the virus. Depletion of CD25+ cells also enhanced IFN-
γ production and the level of protection induced by a
malaria vaccine in mice [refs. in [21]].
6. Improving antigen presentation, activation of 
co-receptors
Reduced DC activity might represent another hurdle to
be overcome in developing successful vaccination strate-
gies for the elderly. Many active immunotherapy proto-
cols for cancer patients rely largely on antigen presenting
DCs to be recruited to the site of vaccination and take up
vaccine antigen, and the same is likely to be true when
immunotherapy is used to combat an infectious agent [7].
Aged CD4+ T lymphocytes have decreased CD40L, a crit-
ical co-stimulatory ligand for T-B cell interactions. IL-2Ongrádi and Kövesdi Immunity & Ageing 2010, 7:7
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enhances CD40L expression [70]. In aged individuals, the
expression of CD134, a TNF receptor family member, on
T cells is reduced. Co-stimulation of CD134 increases T
lymphocyte function, survival, expansion and develop-
ment into memory cells [71]. The increased proportion of
CD8+ T lymphocytes lacking expression of the co-stimu-
latory receptor CD28 leads to autoimmune diseases such
as rheumatoid arthritis, diabetes mellitus, and multiple
sclerosis, some types of cancer such as melanoma, and
chronic infection with viruses such as HIV, hepatitis B
virus (HBV) and CMV [refs. in [7]], decreased vaccine
responsiveness and early mortality [72]. CD28 loss is the
most consistent immunological marker of ageing. In
pathological states, CD28 negative T cells represent pre-
maturely senescent cells resulting from permanent
immune activation [9]. These cells are potent producers
of proinflammatory cytokines, acquire cytolitic capabil-
ity, and have shorter telomeres than their normal coun-
terparts [8]. The loss of CD28 expression on T cells
correlates with an increased expression of CD95 and,
consequently, with an accumulation of CD95+ T cells.
The latter show a reduced susceptibility to apoptosis,
probably due to decreased production of CD95 ligand
after activation and upregulation of several anti-apoptosis
Bcl-2 family members [9]. T cells that have undergone
clonal exhaustion after chronic viral infection also
express the B7-family receptor named programmed cell
death-1 (PD-1), that inhibits co-stimulatory signals. It has
been suggested that blocking PD-1-mediated signalling
could lead to improved T cell functions [73]. Collectively,
these data indicate that stimulation via co-receptors/co-
stimulatory molecules might overcome some of the
intrinsic defects of immune responses in the aged [25].
7. Restoration of thymus functions
Reversion or block of age-related atrophy of the thymus
might be one of the promising therapeutic measures to
reconstitute immune functions in the elderly. It was
reported that in mice transplantation of aged thymuses
into juvenile recipients led to reconstruction of the struc-
ture and function of the thymus [74]. Moreover, trans-
plantation of cultured thymic fragments to patients with
DiGeorge syndrome who lack a functional thymus has
been carried out successfully [74] and may also be a con-
ceivable approach to restore naive T lymphocyte num-
bers in the elderly. Given the paucity of naive T cells in
the elderly, enhancement of thymic output is likely to be a
key requirement for maintaining and restoring their
effective immunity. Neonatal thymuses grafted under the
kidney capsule of mice exported considerable numbers of
T cells [7]. The biological pathways that control thymic
cytokine microenvironment and thymic epithelium rep-
resent candidate targets for therapies to modify age-
induced thymic involution. Enhancing thymic export of T
lymphocytes will theoretically increase the ability to
mount successful immune responses to any antigen.
Inclusion in a vaccine formulation of agents to enhance
thymopoiesis may prove very useful in promoting a
robust, broad T cell response to any antigen (viral, bacte-
rial, parasite, tumour) for which a successful vaccine is
needed. Reversing the decline in the immune response
could also be achieved by removing senescent immune
cells, therefore eliminating any potential detrimental
effect deriving from these cells and permitting their
replacement with naive lymphocytes through the thymic
output. As seen above, there are several potential
approaches to reversing thymic atrophy and increasing
the number of recent thymic emigrants but very few for
removing senescent cells [75]. If the elderly must rely on
their memory T cells for pathogen control in later life, it
becomes crucial to know whether these cells are retained
and function normally [76]. In mice, depletion of dys-
functional naive T cells can readily result in their replace-
ment by functional recent thymic emigrants [77].
8. Stimulation of the impaired immune system by 
cytokines and hormones
Artificial replacement of cytokines, chemokines, and
some of the hormones having a basic role in maintaining
healthy the immune system or their induction by drugs
might prevent or at least partially reconstitute immune
impairment in the elderly. IL-7 seems to be the most
important of such factors to protect and stimulate B and
T cells. The decline in IL-7 expression levels that occurs
in the elderly makes it a target for therapeutic interven-
tions to rejuvenate thymopoiesis. It has been shown that
IL-7 can reverse thymic atrophy in old animals, ensuring
increased thymic output to replenish the peripheral T
lymphocyte pool and improving immune responses [78].
Human IL-7 administration to young mice (aged 6-8
weeks) minimally increased thymopoiesis and peripheral
T cell expansion [79], but the direct subcutaneous injec-
tion of IL-7 does not result in sufficiently high concentra-
tions of the molecule in the thymus. To overcome this
problem the ideal would be targeting IL-7 to the thymus
by creation of a fusion protein. The molecule CCL25 is
produced in the thymus and binds to the chemokine
receptor CCR9, for which it is the only known ligand. A
fusion protein between the extracellular portion of CCR9
and IL-7, when used as a therapeutic agent in old animals,
resulted in its accumulation in the thymus, the reversal of
age-associated thymic atrophy, a significant increase in
the production of new T lymphocytes, and a significant
improvement in antiviral responses [80]. Mice treated
with the fusion protein had a lower viral load in their
lungs compared with sham-treated counterparts follow-
ing influenza virus infection. Based on studies in mice
and monkeys, local delivery of this cytokine to the thy-Ongrádi and Kövesdi Immunity & Ageing 2010, 7:7
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mus by implantation of genetically engineered stromal
cells secreting IL-7 may be a way of avoiding undesired
systematic effects [81]. Clearly, IL-7 has an important role
in thymic functioning, and the above findings indicate
that modulation of IL-7 is feasible and may offer an
approach to increasing the response to vaccination in the
elderly.
By studying other biological response modifiers, it has
been shown that intrathymic injection of an IL-10
expressing adenovirus can prevent thymocyte apoptosis
and the thymic atrophy induced by sepsis in mice [82].
Leptin protects against bacterial endotoxin-induced thy-
mic atrophy [61]. Keratinocyte growth factor (KGF) and
thymic stromal lymphopoietin (TSLP), which is known to
stimulate thymus stromal cells, can promote thymopoie-
sis in mice following chemotherapy-induced thymic atro-
phy [83]. The growth hormone has also been shown to
have a stimulatory effect on thymopoiesis in old mice and
ablative/bone marrow transplant mice [84]. Together,
these studies suggest that coupling thymostimulatory
regimens such as IL-10, leptin, KGF and TSLP with inhi-
b i t i o n  o f  t h y m o s u p p r e s s i v e  c y t o k i n e s  [ s e e  r e f s .  i n  [ 7 ] ]
may be efficacious in the reconstruction of an aged
immune system [25]. Thymic epithelial cells, which are
required to support thymocyte maturation, undergo
apoptotic death in the aged thymus, through a pathway
involving interactions between Fas and Fas ligands.
Because age-associated thymic involution is reported not
to occur in aged Fas-deficient mice [85], blocking this
pathway locally in the thymus might also contribute to
retaining thymic functionality. The same may apply to
tumour growth factor (TGF)-β2, as greater cellularity and
higher levels of naive T lymphocytes are seen in old TGF-
β2-deficient mice compared to old wild-type mice [86].
IL-2 and IL-4 might restore the proliferative capacity of
aged B cells [47]. Naive T cells from old animals do seem
to be impaired, as CD4+ T lymphocytes show decreased
helper activity and IL-2 production, but both these activi-
ties can nevertheless be partially restored by exposure to
a mixture of pro-inflammatory cytokines (IL-1, IL-6,
TNF) [87]. Thus, judicious local use of these cytokines as
adjuvants might be beneficial. However, in elderly
humans there may be vanishingly few naive cells remain-
ing that could be targeted in this way. On the other hand,
some workers recommend the opposite, because the use
of anti-inflammatory agents to decrease the levels of IL-1,
IL-6 and TNF may also assist in rebalancing immunity;
e.g. statins are already being used extensively in the
elderly to treat autoimmune responses [88]. However, the
efficacy of any approach to influence inflammation is
very much open to question, as inflammation also has
protective effects against pathogens.
Concerning the effect of hormones on the dysfunc-
t i o n a l  a g e d  i m m u n e  s y s t e m ,  i t  h as  be e n  d e m o n s t r a t ed
that significant boosts in cellularity and decreased adi-
p o s i t y  o f  b o n e  m a r r o w  o c c u r r e d  i n  a g e d  m i c e  t r e a t e d
with recombinant growth hormone. In addition to its
ability to stimulate aged bone marrow stroma, this hor-
mone can also have a positive effect on early T cell lin-
eage progenitors and stimulate thymopoiesis in aged
mice, bone marrow transplant mice, and bone marrow
colonised foetal thymus organ cultures [84]. Sex steroid
ablation in men undergoing therapy for prostate cancer is
reported to result in increased numbers of circulating
naive T lymphocytes, but this approach is obviously not
generally applicable to the majority of elderly people [7].
Similarly, it has been known since ancient times that
eunuchs live longer than normal males, perhaps due to
preserved immune functions.
9. Persistent microbial infections may contribute to 
immune exhaustion
Several environmental factors may drive T cell senes-
cence in vivo, among which are infections with immuno-
suppressive viruses that establish latency such as CMV,
EBV, HBV and HCV. These viruses can chronically stim-
ulate T cells and may be responsible for the presence of
oligoclonally expanded virus-specific CD8+ T cells, the
majority of which dysfunctional or anergic, in the elderly
[5,7,9,89]. CMV infection may have an especially signifi-
cant impact on immune parameters in later life. There is
some epidemiological evidence for excess mortality in
CMV seropositive populations, which is further
increased in those co-infected with hepatitis A and B as
well. CMV seropositive individuals also have higher levels
of CRP, indicating that they are more likely to suffer with
chronic inflammation. However, it is obvious that immu-
nosenescence is not caused by CMV, because not all
elderly people are CMV positive [33]. A recent study has
also shown a progressive accumulation of HSV specific T
cells with a central memory phenotype and exhaustion in
old mice. However, continuous administration of antiviral
drugs did not alter the course of this accumulation of T
cells. These mice have a shorter remaining survival time
than people of the same age with fewer of these cells.
These finding suggests that eventual loss of control of
herpesvirus infections after a lifetime of immunosurveil-
lance may indeed be a cause of mortality in the elderly
population [7,90]. It is noteworthy that analogous phe-
nomena of clonal exhaustion and senescence may also
occur in HIV infection [91]. In some respects, AIDS may
also be regarded as an extremely accelerated, premature
ageing. Other human pathogens may play a similar role.
Human herpesvírus (HHV) 6, variants A and B, infect
CD4+ T lymphocytes and macrophages and establish life-
long latency and persistence in these cells. HHV-6A
transactivates HIV enhancing AIDS progression and
oncogenic human papillomavirus types facilitating cervi-Ongrádi and Kövesdi Immunity & Ageing 2010, 7:7
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cal cancer development. HHV-6A, along with CMV, is
frequently reactivated in immunocompromised patients,
especially transplant recipients aggravating their CMV
disease. HHV-6 variants are believed to be cofactors in
chronic disorders such as multiple sclerosis and lympho-
mas frequently seen in elder people. HHV-7 infects CD4+
T lymphocytes alone, establishes life-long persistence
and reactivates HHV-6. The products of early genes of
HHVs and consequently, the altered cytokine release by
infected cells play roles in the transactivating effect on
other viruses [92]. It is conceivable that the persistent
infections by these and other viruses contribute to the
continuous antigenic stress and exhaustion of the
immune system. In this regard, it is worth recalling that
molecular techniques have recently greatly expanded the
list of viruses that produce chronic productive infections
in humans. A most interesting example is provided by the
vast array of small unenveloped single-stranded DNA
viruses that are currently classified within the family
Anelloviridae. An amazing epidemiological feature of
these newly recognized viruses is that they produce an
apparently life-long high-titre, often mixed plasma virae-
mia in essentially all people regardless of age, health sta-
tus and other variables. The prototypes of these viruses,
torquetenoviruses, have been shown to replicate exten-
sively, if not solely in haematopoietic cells, and it is
believed that the other members of the family share the
same tropism. Although formal proof has yet to be
obtained similar to all the other viruses that lack an exter-
nal cell-derived envelope, the anelloviruses are likely to
be cytocidal for the cells in which they replicate. In any
case, their florid replication in the haematopoietic cell
compartment throughout life may represent a remarkable
stress for the progenitor and precursor cells from which
all the immune cells originate. In turn, even though the
formidable regenerative potential of haematopoietic cells
may prevent the clinical emergence of cell damage for
long periods of time, in the long run this continued repli-
cation is likely to contribute significantly to the decay of
immune responsiveness that becomes appreciable late in
life [93]. Long-term exposure to other persistent stimu-
lating agents, including parasite antigens especially
important in developing countries, may yield similar
effects [7].
Strategies to reduce the chronic infectious antigenic
load would seem to offer a reasonable approach to restor-
ing appropriate immune functions and might also benefit
naive T cell production. Targeting these viruses and any
other infectious agents that have established a persistent
infection may be of clinical benefit both directly by
reducing the pathological consequences of the infections
and in terms of improving responses to vaccinations.
Unfortunately, the continuous administration of antiviral
drugs did not alter the course of progressive accumula-
tion of virus-specific exhausted memory T cells in old
mice [7]. As CMV persistency and influenza virus infec-
tion may exert especially detrimental effects on the
immune system in the elderly, studies have focused on
attempts to eliminate their effects. The putatively dys-
functional CMV-specific CD8+CD28+  T lymphocytes
that accumulate in the elderly and that seem to be anergic
and apoptosis-resistant may be restored to functional
competence directly ex vivo by culturing them with IL-2.
In this respect, they behave like anergic T cells that can be
found in many experimental situations of chronic antigen
exposure; notably, in at least some such situations several
approaches, including the blocking of inhibitory recep-
tors such as PD-1, can restore T lymphocyte functions
[94]. One option, again, could therefore be to treat the
elderly with recombinant IL-2: an early study reported
that elderly people given well tolerated low doses of IL-2
just before receiving influenza virus vaccination pro-
duced higher antibody titres and were better protected
then controls vaccinated without IL-2 pre-treatment [95].
A recent study using a novel IL-2 supplemented lipo-
somal influenza vaccine in a group of elderly people also
found superior responses with the use of IL-2 [96].
10. Problems and new possibilities with 
vaccination in the elderly
One of the greatest practical health-care challenges in the
elderly is to ensure that vaccinations are optimally effec-
tive. Increasing the efficacy of vaccination would have an
enormous impact on health and well-being [7]. Develop-
ment of vaccination strategies that are effective in all age
groups is an important area of research, particularly to
protect against new or re-emerging fatal infections and
possible infectious agents that might be weaponised by
bioterrorists [97]. Investigations on the adequateness of
responses to vaccination require longitudinal studies fol-
lowing the same individuals over time and correlating test
parameters with clinical outcome (including responses to
the vaccine, pathology and disease-specific lethality). Bet-
ter vaccine efficacy in the elderly may require a two-
pronged attack on the problem, consisting of an improve-
ment in the immune responsiveness and an alteration to
vaccine formulations. Vaccination can only be effective if
cells that are capable of responding are still present in the
repertoire [7]. Unfortunately, immunosenescence also
compromises the response to vaccination. Since the
elderly comprise the largest target population for influ-
enza vaccination, the majority of studies evaluating the
efficacy and benefits of vaccination have been conducted
among people in this age group [98]. Influenza is the fifth
leading cause of death in the developed world among
people aged 50 and older, and this group is the major tar-
get of vaccination campaigns [4,99]. This vaccination
strategy is controversial, as it appears to have only a mod-Ongrádi and Kövesdi Immunity & Ageing 2010, 7:7
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erate impact on influenza-specific immune responses and
infection rates in this group [100]. While influenza vacci-
nation has 70-90% efficacy in healthy adults in Western
countries, the success rate falls to 17-53% in the elderly
[101] when determined as specific immune responses.
Further data show that in people aged 65 years and over,
effectiveness measured by the prevention of influenza-
like illness is 23%, while in healthy children (aged > 2
years) the effectiveness is higher, at 38% [20]. The effect
of influenza vaccination on the risk of pneumonia in
elderly people during influenza seasons might also be less
than previously estimated [4]. The reasons for these
unsatisfactory outcomes of vaccination have been clearly
established: both the humoral and cell-mediated influ-
enza-specific responses are lower than in young adults
[98]. Peripheral blood mononuclear cells from elderly
adults (> 65 years) stimulated with influenza A virus ex
vivo  exhibited a decrease in IFN-γ+ T cells and in the
secretion of IFN-γ by individual cells when compared to
young adults (aged 20-50 years). Expansion of CD8+ T
cells was also reduced in the aged, who also produced
fewer antibodies in response to influenza virus [102]. In
mouse models, influenza virus is cleared from the lungs
more slowly in old than in young animals, apparently due
to decreased cytotoxic T cell production. Cell transfer
experiments demonstrated that both the old cells and the
old microenvironment of cells contribute to the problem;
indeed, even young functional T cells did not respond
properly when transferred to an old individual, and nei-
ther did old cells when transferred to a young subject
[103]. Patient-individualised strategies will have to take
the immunological age of the person closely into account.
For this, it will be necessary to differentiate between
chronological and functional age of immunity, an assess-
ment that could be based on a constellation of immune
markers [7]. In the case of new influenza vaccines tar-
geted for use in the elderly, improvement of the formula-
tions are primarily sought at the level of T cell immunity
[98]. During the course of an influenza virus infection,
bacterial superinfections often represent the ultimate
determinant of morbidity and mortality. Post-mortem
examination of fatal confirmed pandemic H1N1 2009
influenza demonstrated evidence of coexistent bacterial
infection in nearly one third of cases. An impairment of
the TLRs and/or APCs can be pivotal in the genesis of
these bacterial complications [104].
The second prong on the assault on the problem would
be to develop vaccines especially designed for the elderly.
Several strategies have been explored, including the use
of high dose of the immunogens [105], DNA vaccines
with immunostimulatory patch [106], recombinant virus-
like particles (e.g. the vaccine against human papilloma
viruses [6]), virosomal vaccines [107], and adjuvant vac-
cines [108]. Virosomes represent a novel vaccine presen-
tation form that closely mimic a native virus. They are
virus-like particles consisting of reconstituted viral enve-
lopes or capsids lacking the viral genetic material and
bind and fuse to different target cells including immune
cells. Virosomes can deliver encapsulated protein anti-
gens or even large transfecting plasmid DNA to the cyto-
sol. Protein antigens might thus bypass the potential
problem of MHC restriction and induce strong CTL
responses. Foreign antigens that may be coupled to the
surface of virosomes can be recognised by membrane-
associated Ig receptor molecules on B lymphocytes.
Influenza-derived virosomes stimulated co-stimulatory
signaling, for example B7.1 (CD80), B7.2 (CD86), CD40,
MHC class I and class II expression on DCs. Intact viri-
ons of inactivated hepatitis A virus (HAV) were non-
covalently coupled to the surface of influenza virosomes,
and this combined vaccine induced seroconversion in
100% with high and long-lasting HAV-specific antibody
titres [98]. Virosomes containing amphiphilic adjuvants
incorporated into their membrane offer the additional
advantage of combining APCs activation with presenta-
tion of the antigen by the same cells. A combined influ-
enza virosome vaccine was recognised by TLR-2, which is
present on B lymphocytes and DCs. In mice, a single
injection resulted in a 150-fold increased IgG response
compared to virosomes lacking the adjuvant [98]. Adju-
vanted influenza vaccines, such as those containing oil-
in-water emulsion (e.g. squalene, Tween 80 and sorbitan
triolerate [98]), will have an important role, because they
have been shown to induce stronger and more effective
serologic responses in the elderly than conventional non-
adjuvanted vaccines, not only against homologous but
also against heterovariant strains [108]. The H5N1 pre-
pandemic influenza virus strain administered with an oil-
in-water adjuvant emulsion generated a more robust
immune response compared to the non-adjuvanted ver-
sion in a preclinical trial [104]. Adjuvants may also reduce
the dose requirements for vaccine antigen, a factor of par-
ticular importance in the context of a much increased
demand for vaccine in a pandemic situation [98,104]. Fur-
thermore, a combination of improved vaccines with bet-
ter adjuvants and immunostimulatory agents would be of
increased benefit, as the commonly applied adjuvant
alum is only marginally effective in the elderly [109]. A
pandemic H1N1 2009 inactivated influenza virus strain
adjuvanted with alum enhanced immunogenicity only
moderately [104]. Indeed, alum mainly enhances anti-
body responses, whereas resistance to viruses and cancer
may benefit from enhanced cell-mediated immunity.
Adjuvanted vaccines strongly support the notion that
superior vaccines can be designed with the aim of over-
coming immunosenescence and/or improving protec-
tion in the elderly population [1]. Interestingly, TLR
ligands can direct the immune response into specificOngrádi and Kövesdi Immunity & Ageing 2010, 7:7
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directions; therefore, they also have a great potential as
adjuvants. TLR agonists can block the anti-inflammatory
arm of the innate immune responses and are rapidly
emerging as potential adjuvants for enhancing the immu-
nogenicity of subunit vaccines. When applied to infec-
tious disease and tumour models, the adjuvant
combination of a TLR agonist and a p38 MAPK inhibitor
suppressing IL-10 and prostaglandin E2 production by
DCs, considerably enhanced vaccine efficacy, selectively
inhibiting the Treg promoting arm of innate immunity
[6,21]. Much work is also focused on optimising delivery
systems for TLR ligands to enhance their adjuvanticity
[6].
The cancer vaccines that are currently under develop-
ment differ from the vast majority of those against infec-
tious diseases, because they are administered after the
onset or detection of disease, thus they are correctly
regarded as therapeutic rather than prophylactic vac-
cines. They contain tumour cell lysates or defined cancer
antigens. The latter vaccines are usually a single antigen
that is delivered by one of a number of delivery systems
that include recombinant proteins and viral vectors, pep-
tides, or ex vivo treated DCs. Another new field is the
vaccine-like approach that is being explored as a means of
containing Alzheimer disease. Since the plaques depos-
ited in the brain of patients originate from a neuronal
membrane-bound protein, the amyloid precursor pro-
tein, experimental vaccines consist of analogues of the β-
amyloid peptide coupled to a carrier. The aim is to raise
antibodies which recognise plaques, Aβ deposits and β-
amyloid in brain blood vessels, but do not see the amyloid
precursor protein or Aβ [6].
11. Concluding remarks
Frequent and severe microbial infections influence the
quality of life of elderly individuals and their families, and
have a deleterious financial impact onto the health-care
system. Theoretically, several types of infectious diseases
might be prevented by vaccinating old people. Lately it
has become evident that vaccination or re-vaccination in
this age group is not only a political agenda or financial
matter, because age-related alterations of the immune
system would render most vaccines ineffective in the
majority of subjects. An improved understanding of
immune dysfunction in human ageing will increase the
probability of discovering means to restore appropriate
function and alleviate the burden of infectious diseases
later in life. Prevention of immunosenescence or at least
partial reconstitution of the immune activities are
required if a vaccination regimen is introduced in these
people, who very often suffer of multiple important
comorbidities. Experimental data and clinical observa-
tions outlined above demonstrate that both innate and
adaptive immunity can be improved in the elderly. Any
successful intervention might possibly boost other
immune reactions due to several feed-back mechanisms.
Activation of the exhausted immune system by using
cytokines and judicious application of hormones appear
to be promising practical approaches to combat chronic
infection with immunosuppressive persistent viruses.
Furthermore, new types of vaccine formulation, espe-
cially virosomal vaccines and adjuvanted vaccines, permit
improved antigen presentation and cytotoxic activity
against intracellular pathogens. Hopefully, at least some
of the approaches outlined here will be translated to
human medicine in a not too far future.
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